Author

Paul Ellis

Institutions: King's College London, AbbVie (United States), Kings Health Partners

Observed institutions: King's College London, AbbVie (United States), Kings Health Partners

ORCID: 0009-0004-9761-7628

Observed ORCID: 0009-0004-9761-7628

OpenAlex ID: A5133839743

Immunodominant Antiviral T-cell Responses Outcompete Antitumor T-cell Responses to Reduce the Efficacy of Oncolytic Viroimmunotherapy

2026 · Benjamin L. Kendall, Olivia Y. Liseth, et al. · Cancer Research

Abstract LB253: Discovery of A-911, a potent, orally bioavailable 5-HT7 antagonist that promotes DC1-mediated T-cell cross-priming and anti-tumor immunity

2026 · Kenneth D. Bromberg, Jacob Gorman, et al. · Cancer Research

Works count: 2

Citation count:

H-index:

I10-index: